IMC-002
- Generic Name
- IMC-002
Shionogi to Acquire Japan Tobacco's Pharmaceutical Subsidiaries for $1.1 Billion
• Shionogi & Co. plans to acquire Japan Tobacco's pharmaceutical subsidiaries Torii Pharmaceutical and Akros Pharma for ¥160 billion ($1.1 billion) to strengthen its global R&D capabilities.
• The acquisition, negotiated since early 2024, will proceed through a tender offer beginning June 18 with a share price of ¥6,350 to acquire at least 11.89% of the minority stake.
• This strategic move represents significant consolidation in the Japanese pharmaceutical sector and expands Shionogi's market presence amid increasing global competition.
CD47-Targeted Immunotherapies Show Promise in Cancer Treatment
• CD47-targeted therapies are emerging as a novel cancer immunotherapy approach, inhibiting the "don't eat me" signal that cancer cells use to evade immune surveillance.
• Several CD47 inhibitors, like magrolimab and evorpacept, are undergoing clinical trials, showing encouraging results in hematological and solid tumors, often in combination with other treatments.
• Regulatory bodies are supportive, granting fast track designations and IND clearances, indicating a rapidly expanding CD47 market driven by the rising incidence of cancer.
• Pharmaceutical companies and research institutions are actively involved, with the United States leading the sector, while countries like China are increasing their engagement in clinical studies.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath